Starlix

OVERDOSE

In a clinical study in patients with Type 2 diabetes, Starlix® (nateglinide)
was administered in increasing doses up to 720 mg a day for 7 days and there
were no clinically significant adverse events reported. There have been no instances
of overdose with Starlix in clinical trials. However, an overdose may result
in an exaggerated glucose-lowering effect with the development of hypoglycemic
symptoms. Hypoglycemic symptoms without loss of consciousness or neurological
findings should be treated with oral glucose and adjustments in dosage and/or
meal patterns. Severe hypoglycemic reactions with coma, seizure, or other neurological
symptoms should be treated with intravenous glucose. As nateglinide is highly
protein bound, dialysis is not an efficient means of removing it from the blood.